IRVINE, Calif.--(EON: Enhanced Online News)--Khang & Khang LLP (the “Firm”) announces that it is investigating claims against Stemline Therapeutics, Inc. (“Stemline” or the “Company”) (Nasdaq: STML) concerning possible violations of federal securities laws.
If you purchased shares of Stemline and want more information free of charge, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at email@example.com.
On February 2, 2017, Bloomberg disclosed that a patient in a clinical trial of Stemline’s cancer drug SL-401 died from a side effect. This is the third death linked to SL-401 toxicity. When this information was announced to the public, the value of Stemline stock fell significantly, causing investors severe harm.
If you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at firstname.lastname@example.org.
This press release may constitute Attorney Advertising in some jurisdictions.